Marina Biotech Inc (MRNA) - Financial and Strategic SWOT Analysis Review

May 2018 | 43 pages | ID: M57A59C57E6EN
GlobalData

Abstracts

Marina Biotech Inc (MRNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Marina Biotech Inc (Marina) is a nucleic acid-based drug discovery and development company that focuses on rare diseases. It focuses on treating the intersection of arthritis, hypertension, pain, and cancer using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. Based on its drug discovery platform, SMARTICLES Marina develops proprietary single and double-stranded nucleic acid therapeutics including microRNA mimics, siRNAs, antagomirs and antisense compounds envisioned to activate various RNA-based mechanisms of action. The company is developing CEQ508 in Phase I clinical studies for treating patients with familial adenomatous polyposis (FAP). Marina is headquartered in City of Industry, California, the US.

Marina Biotech Inc Key Recent Developments

Aug 21,2017: Windlas Healthcare Invests $2 Million in Working Capital to Support Marina Biotech’s Manufacturing Initiatives
Jul 05,2017: Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman
Jun 26,2017: Marina Biotech appoints chief commercial officer to lead sales and marketing of Prestalia
Jun 26,2017: Marina Biotech appoints chief commercial officer
May 30,2017: Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Marina Biotech Inc - Key Facts
Marina Biotech Inc - Key Employees
Marina Biotech Inc - Key Employee Biographies
Marina Biotech Inc - Major Products and Services
Marina Biotech Inc - History
Marina Biotech Inc - Company Statement
Marina Biotech Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Marina Biotech Inc - Business Description
Marina Biotech Inc - Corporate Strategy
Marina Biotech Inc - SWOT Analysis
SWOT Analysis - Overview
Marina Biotech Inc - Strengths
Marina Biotech Inc - Weaknesses
Marina Biotech Inc - Opportunities
Marina Biotech Inc - Threats
Marina Biotech Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Marina Biotech Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 21, 2017: Windlas Healthcare Invests $2 Million in Working Capital to Support Marina Biotech’s Manufacturing Initiatives
Jul 05, 2017: Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman
Jun 26, 2017: Marina Biotech appoints chief commercial officer
May 30, 2017: Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases
Apr 05, 2017: Marina Biotech Provides Business Update
Feb 21, 2017: Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer
Feb 14, 2017: Marina Biotech Announces Key Additions to its Executive Management Team

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Marina Biotech Inc, Key Facts
Marina Biotech Inc, Key Employees
Marina Biotech Inc, Key Employee Biographies
Marina Biotech Inc, Major Products and Services
Marina Biotech Inc, History
Marina Biotech Inc, Subsidiaries
Marina Biotech Inc, Key Competitors
Marina Biotech Inc, Ratios based on current share price
Marina Biotech Inc, Annual Ratios
Marina Biotech Inc, Annual Ratios (Cont.1)
Marina Biotech Inc, Interim Ratios
Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Marina Biotech Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Marina Biotech Inc, Performance Chart (2013 - 2017)
Marina Biotech Inc, Ratio Charts
Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Marina Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Silence Therapeutics Plc
Regulus Therapeutics Inc
Quark Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Arbutus Biopharma Corp
Arbor Pharmaceuticals LLC
Alnylam Pharmaceuticals Inc
Allergan Plc